Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Payables (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Payables for 7 consecutive years, with $11.2 million as the latest value for Q4 2025.

  • Quarterly Payables rose 154.42% to $11.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.2 million through Dec 2025, up 154.42% year-over-year, with the annual reading at $11.2 million for FY2025, 154.42% up from the prior year.
  • Payables for Q4 2025 was $11.2 million at 4D Molecular Therapeutics, up from $6.9 million in the prior quarter.
  • The five-year high for Payables was $11.2 million in Q4 2025, with the low at $1.3 million in Q1 2021.
  • Average Payables over 5 years is $4.1 million, with a median of $3.5 million recorded in 2023.
  • The sharpest move saw Payables plummeted 60.14% in 2022, then soared 218.45% in 2023.
  • Over 5 years, Payables stood at $4.8 million in 2021, then tumbled by 30.27% to $3.3 million in 2022, then grew by 5.81% to $3.5 million in 2023, then rose by 24.78% to $4.4 million in 2024, then soared by 154.42% to $11.2 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $11.2 million, $6.9 million, and $8.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.